Hostname: page-component-848d4c4894-xm8r8 Total loading time: 0 Render date: 2024-06-19T18:57:51.938Z Has data issue: false hasContentIssue false
  • English
  • Français

Zuclopenthixol-acetate treatment in catatonic patients: the implication of iron metabolism

Published online by Cambridge University Press:  16 April 2020

A. Conca ,
E. Bertsch ,
A. Küng ,
R. Waschgler ,
W. Hrubos ,
P. König  and
M. Hansen
A. Conca*
Affiliation:
Department of Psychiatry I, Regional Hospital Rankweil, 6830Rankweil, Austria
E. Bertsch
Affiliation:
Nurse Unit of Psychiatry I, Regional Hospital Rankweil, 6830Rankweil, Austria
A. Küng
Affiliation:
Department of Psychiatry I, Regional Hospital Rankweil, 6830Rankweil, Austria
R. Waschgler
Affiliation:
Central Medical Laboratory, Feldkirch, Austria
W. Hrubos
Affiliation:
Department of Psychiatry I, Regional Hospital Rankweil, 6830Rankweil, Austria
P. König
Affiliation:
Department of Psychiatry I, Regional Hospital Rankweil, 6830Rankweil, Austria
M. Hansen
Affiliation:
Department of Psychiatry I, Regional Hospital Rankweil, 6830Rankweil, Austria Department of Biostatistics, Regional Hospital Rankweil, 6830Rankweil, Austria
*
*E-mail address: andreas.conca@lkhr.at
Get access

Abstract

There is some evidence of ferropenia correlating with neuroleptic malignant syndrome and catatonic symptoms. The aim of this prospective and naturalistic study was to investigate the implications of ferremia in patients undergoing an intramuscular injection treatment of Zuclopenthixol-acetate in Visceolo. We recruited 59 catatonic patients (33 females). Age, sex, psychiatric and somatic diagnoses, body mass index (BMI), dosage and duration of Zuclopenthixol-acetate medication and the timing of the changeover from intramuscular to oral prescription, the single dosage of Clopenthixol if initially coadministered, incidence, onset and duration of transient benign hyperthermia, iron, ferritin, transferrin and saturation values, and white and red blood cell counts as well as liver function and electrolytes were registered. A transient and benign hyperthermic reaction (mean degrees: 37.5 + 0.3 °C) lasting for an average of 3.0 + 1.9 d was shown by 72.9% patients (N = 43, 22 females), during a mean treatment period of 5.8 + 3.1 d. These patients were medicated with significant different mean doses of Zuclopenthixol-acetate and compared to the patients with normal body temperature (ANOVA P < 0.01). The duration of Zuclopenthixol-acetate application did not vary between these patients groups. Furthermore, significant differences of iron (59.5 + 30.6 μmol/dl vs. 87.8 + 40.8 μmol/dl; ANOVA P < 0.006) and transferrin saturation values (18.3 + 10.4% vs. 27.2 + 17.0%; ANOVA P < 0.02) were found. Ferritin and transferrin were not implicated in the episode of hyperthermia. Diagnoses, sex, white and red blood cell counts also did not vary between these groups. Our findings indicate a possible involvement of ferropenia in catatonic patients, regardless of the diagnoses, and in the development of benign transient hyperthermia, also known as drug fever.

Keywords

CatatoniaHypoferremiaDrug feverZuclopenthixol
Type
Original article
Information
European Psychiatry , Volume 18 , Issue 1 , February 2003 , pp. 28 - 31
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS 2003

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Brown, KW, Glen, SE, Whithe, TLow serum iron status and akathisia. Lancet 1978;ii:1234–7.Google Scholar
Carrol, BT, Goforth, HWSerum iron in catatonia. Biol Psychiatry 1995;38:776–7.CrossRefGoogle Scholar
Conca, A, König, P. The efficacy and tolerability of Zuclopenthixol-acutard in psychotic disorders. Psychiatr Hung 1993;VIII(2): 191–206.Google Scholar
Ekbom, KA. Restless leg syndrome. Neurology 1960;10:868–73.CrossRefGoogle Scholar
Farde, L, Nordstrom, AL, Wiesel, FA, Pauli, S, Halldin, C, Sedvall, GPET analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classic neuroleptics and clozapine relationship to extra pyramidal side effects. Arch Gen Psychiatry 1992;49:538–44.CrossRefGoogle Scholar
Figa-Talamanca, L, Gualandi, C, Di Meo, L, Di Battista, G, Neri, G, Lo Russo, FHyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause. Neurology 1985;35:258–61.CrossRefGoogle ScholarPubMed
Gay, W, Ban, TAThe AMDP-system. A manual for the assessment and documentation in psychopathology. Berlin: Springer Verlag; 1982.CrossRefGoogle Scholar
Dilling, H, Mombour, W, Schmidt, MH, Schulte-Markwort, E editors. Internationale Klassifikation psychischer Störungen: ICD-10, Kapitel V(F); Forschungskriterien/Weltgesundheitsorganisation. 1st ed. Bern: Verl. Hans Huber; 1994.Google Scholar
Lee, JWY. Serum iron in catatonia and neuroleptic malignant syndrome. Biol Psychiatry 1998;44:499–507.CrossRefGoogle ScholarPubMed
Peralta, V, Cuesta, MJ, Mata, I, Serrano, JF, Perez-Nievas, F, Natividad Mari, CSerum iron in catatonic and non-catatonic psychotic patients. Biol Psychiatry 1999;45:788–90.CrossRefGoogle Scholar
Philbrick, KL, Rummans, TAMalignant catatonia. J Neuropsychiatry ClinNeurosci 1994;6:1–13.Google ScholarPubMed
Rosebush, PI, Mazurek, MFSerum iron and neuroleptic malignant syndrome. Lancet 1991;338:149–51.CrossRefGoogle ScholarPubMed
Sachs, LAngewandte Statistik, 7th ed. Berlin: Springer Verlag; 1992.CrossRefGoogle Scholar
Taylor, MA. Catatonia. A review of a behavioral neurological syndrome. Neuropsychiatry Neuropsychol Behav Neurol 1990;3:48–72.Google Scholar
Weller, M, Kornhuber, JSerum iron levels in neuroleptic malignant syndrome. Biol Psychiatry 1993;34:123–4.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.